<?xml version="1.0" encoding="UTF-8"?>
<p id="Par36">WHO guidelines recommend antiviral treatment in uncomplicated influenza in those with risk factors for complicated illness, as well as treatment of patients with severe or progressive clinical presentations of suspected or confirmed influenza.
 <sup>
  <xref ref-type="bibr" rid="CR68">68</xref>
 </sup> Neuraminidase inhibitors (NAIs) are most often used; although adamantanes (amantadine and rimantadine) and ribavirin have activity against some influenza viruses, their use is limited by side-effects and antiviral resistance. Influenza B viruses are generally resistant to adamantanes,
 <sup>
  <xref ref-type="bibr" rid="CR69">69</xref>
 </sup> as are currently circulating seasonal influenza A viruses.
</p>
